Targeted Oncology· @TargetedOnc · X·· 16 hours agoScore70
Body · original
A question for the INTerpath-001 panel:
With neoadjuvant nivo/ipi already transforming melanoma care, where will personalized mRNA vaccines fit?
Should future studies integrate vaccination into neoadjuvant strategies rather than simply intensifying adjuvant therapy?
#ESMO26
118 views · 0 likes · 0 reposts · 0 replies
Conference abstracts
LBA1matched by Presidential Symposium I
INTerpath-001: Phase 3 study of the mRNA-based individualized neoantigen therapy (INT) intismeran autogene (intismeran) plus pembrolizumab (pembro) vs pembro alone for adjuvant treatment of resected stage IIB-IV melanoma (MEL)
https://esmocongress.esmo.orgINTerpath-001
https://esmocongress.esmo.orgSource: Targeted Oncology · x.com